Johnson & Johnson's Q1 2023 earnings call showed strong operational performance across all segments, particularly in MedTech and Consumer Health.  The company raised full-year guidance based on a strong start and positive outlook for consistent performance throughout the year, driven by favorable procedure growth for MedTech, new product launches, and strategic pricing in Consumer Health.  Management expressed confidence in exceeding 2025 Pharma sales targets despite currency headwinds and competitive pressures, thanks to a robust pipeline and new product introductions.
[1]
